PENELOPE-B
PENELOPE-B tested whether a year of the CDK4/6 inhibitor palbociclib after chemotherapy and surgery would prevent recurrence in women at high risk; it did not, one of two trials to show that palbociclib does not work in early breast cancer even though later drugs in the class do.
Overview
PENELOPE-B randomised 1250 women with hormone receptor-positive, HER2-negative breast cancer who still had invasive disease at surgery after neoadjuvant chemotherapy, and a high clinical-pathological risk score, to 13 cycles of palbociclib or placebo alongside standard endocrine therapy. The primary endpoint was invasive disease-free survival.
Palbociclib did not improve invasive disease-free survival; an early separation of the curves disappeared with longer follow-up. Together with PALLAS, which tested two years of palbociclib in a broader population, it showed that palbociclib has no role in early breast cancer, while abemaciclib (monarchE) and ribociclib (NATALEE) proved effective, a reminder that the class does not behave as one drug.
Similar pages
not linked directly; found by shared links- TrialPATINA
Shares Palbociclib, Breast cancer (all types), Pfizer (incl. Seagen), HR-positive / HER2-negative breast cancer and the tag subtype-trials.
- TrialBOLERO-2
Shares Breast cancer (all types), HR-positive / HER2-negative breast cancer and the tag subtype-trials.
- TrialBrighTNess
Shares Sibylle Loibl and the tag subtype-trials.
- TrialTAM-01
Shares Breast cancer (all types) and the tag subtype-trials.
- TrialCOMET (Comparison of Operative versus Monitoring and Endocrine Therapy)
Shares Breast cancer (all types) and the tag subtype-trials.
- TrialATEMPT
Shares Breast cancer (all types) and the tag subtype-trials.
- TrialTUXEDO-1
Shares Breast cancer (all types) and the tag subtype-trials.
- TrialENZAMET
Shares Pfizer (incl. Seagen) and the tag subtype-trials.